Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Mitsubishi Chemical Industries Limited Patents
Assignee:
Mitsubishi Chemical Industries Limited
Address:
Tokyo, JP
No. of patents:
325
Patents:


1 2 3 4 5 6 7










Patent Number Title Of Patent Date Issued
4073914 N.sup.2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof February 14, 1978
N.sup.2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof have been found to be effective as pharmaceutical agents for the inhibition and suppression of thrombosis.
4073913 N.sup.2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof February 14, 1978
N.sup.2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof have been found to be effective as pharmaceutical agents for the inhibition and suppression of thrombosis in mammals.
4073892 N.sup.2 -alkoxynaphthylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereo February 14, 1978
N.sup.2 -alkoxynaphthylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof have been found to be effective as pharmaceutical agents for the inhibition and suppression of thrombosis in mammals, and are prepared by reacting an N.sup.2 -alkoxynaphthylsulfonyl-L-arginy
4073891 N.sup.2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof February 14, 1978
N.sup.2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof have been found to be effective as pharmaceutical agents for the inhibition and suppression of thrombosis in mammals.
4072757 N.sup.2 alkoxynaphthylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof February 7, 1978
N.sup.2 -alkoxynaphthylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof have been found to be effective as pharmaceutical agents for the inhibition and suppression of thrombosis in mammals.
4072744 N.sup.2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof February 7, 1978
N.sup.2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof have been found to be effective as pharmaceutical agents for the inhibition and suppression of thrombosis in mammals.
4072743 N.sup.2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof February 7, 1978
N.sup.2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof have been found to be effective as pharmaceutical agents for the inhibition and suppression of thrombosis in mammals.
4072636 Process for preparing smoke-retardant polyisocyanurate foam February 7, 1978
In a process for preparing a smoke-retardant polyisocyanurate foam by reacting an organic polyisocyanate in the presence of a blowing agent and an isocyanate-trimerization catalyst, an improvement is characterized in that the reaction is conducted in the presence of an organosilicate hav
4071621 N.sup.2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts the January 31, 1978
N.sup.2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof have been found to be effective as pharmaceutical agents for the inhibition and suppression of thrombosis in mammals.
4071568 Process for producing glycol monoether January 31, 1978
Glycol monoethers are produced in high yields by reacting an acetal with carbon monoxide and hydrogen in the presence of a catalyst comprising a cobalt compound and a trivalent organic phosphorus compound or a bidentate chelate ligand containing nitrogen or oxygen. An aldehyde or a compo
4071559 Pharmaceutically active 2-omega-aminoalkoxydiphenyls January 31, 1978
2-Omega-aminoalkoxydiphenyls are prepared and found useful as pharmaceutical agents, particularly as antidepressants.
4069329 N.sup.2 -Naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid ad January 17, 1978
N.sup.2 -naphthalenesulfonyl-L-arginine esters and amides having the formula ##STR1## or the acid addition salts thereof with a pharmaceutically acceptable acid, wherein R is selected from the class consisting of (1) alkoxy, alkenyloxy, cycloalkoxy and halogenated alkoxy, aralkyl
4066759 N.sup.2 -naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid ad January 3, 1978
N.sup.2 -naphthalenesulfonyl-L-arginine esters and amides having the formula ##STR1## or the acid addition salts thereof with a pharmaceutically acceptable acid, wherein R is selected from the class consisting of (1) alkoxy, alkenyloxy, cycloalkoxy and halogenated alkoxy, respect
4066758 N.sup.2 -naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid ad January 3, 1978
N.sup.2 -naphthalenesulfonyl-L-arginine esters and amides having the formula ##STR1## or the acid addition salts thereof with a pharmaceutically acceptable acid, wherein R is selected from the class consisting of (1) alkoxy, alkenyloxy, cycloalkoxy and halogenated alkoxy, respect
4062963 N.sup.2 -naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid ad December 13, 1977
N.sup.2 -naphthalenesulfonyl-L-arginine esters and amides having the formula ##STR1## or the acid addition salts thereof with a pharmaceutically acceptable acid, wherein R is selected from the class consisting of (1) alkoxy, alkenyloxy, cycloalkoxy and halogenated alkoxy, respect
4062900 Process for preparing butanediol and/or butenediol December 13, 1977
Butanediol and/or butenediol are prepared by hydrolyzing diacetoxybutane and/or diacetoxybutene in the presence of a cation-exchange resin and recovered by fractional distillation. By the treatment of the hydrolyzed product with an anion exchange resin at any stage before the butanediol
4051178 Process for producing terephthalic acid September 27, 1977
There is disclosed a process for producing terephthalic acid in which the reaction temperature range and the proportion of catalyst components of a cobalt compound, a manganese compound and at least one bromine compound are specifically chosen to produce a high grade terephthalic acid su
4049820 Substituted urazole and thiourazole compounds as agricultural fungicidal agents September 20, 1977
There is disclosed a fungicide comprising, as the active ingredient, a 1,2-alkylene-4-(3',5'-dichlorophenyl) urazole derivative suitable for preventing various diseases of plants including fruit trees, vegetables, rice plants and beans.
4049645 N.sup.2 -naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid ad September 20, 1977
N.sup.2 -naphthalenesulfonyl-L-arginine esters and amides having the formula ##STR1## or the acid addition salts thereof with a pharmaceutically acceptable acid, wherein R is wherein R.sub.1 and R.sub.2 are members selected from the class consisting of hydrogen, alkyl, aryl, alk
4046876 N.sup.2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts the September 6, 1977
N.sup.2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof have been found to be effective as pharmaceutical agents for the inhibition and suppression of thrombosis.
4042409 Water repellent gypsum composition August 16, 1977
A water repellent gypsum composition comprising a gypsum, and a paraffin emulsion prepared by emulsifying (a) paraffin hydrocarbon having a melting point of 40.degree.-80.degree. C and (b) an oxidized paraffin having an acid value of 10-70 at a ratio of from 97:3 to 50:50 by weight,
4041156 N.sup.2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts the August 9, 1977
N.sup.2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof have been found to be effective as pharmaceutical agents for the inhibition and suppression of thrombosis.
4041082 Process for producing aldehydes August 9, 1977
In a process for producing an aldehyde by hydroformylation comprising reacting an olefin with carbon monoxide and hydrogen in the presence of a solution of a rhodium-tertiary phosphine complex catalyst and recycling the catalyst-containing solution to the reaction zone after recovering t
3939186 Process for producing ethers of steroids February 17, 1976
A process for producing a steroid ether which comprises admixing an alkali, a reactant steroid having a hydroxyl group attached directly to an aromatic ring in the steroid nucleus, and a dialkyl sulfate in the presence of at least one hydrophilic solvent in which said reactant and pr
3932538 Process for producing pyrogallol and derivatives thereof January 13, 1976
A process for producing pyrogallol or 5-substituted pyrogallol having the formula: ##SPC1##Wherein R is selected from the group consisting of alkyl, cycloalkyl, aryl, and aralkyl, or a mixture thereof which comprises heating an aqueous solution of 4-substituted-2,6-diaminophenol or 4
1 2 3 4 5 6 7

 
 
  Recently Added Patents
Vectorization of program code
Methods and devices for creating, compressing and searching binary tree
Program recording medium, image processing apparatus, imaging apparatus, and image processing method
System and method for detecting states
Method for execution upon processing of at least one histological sample
Probe for ultrasound diagnostic apparatus
Transmission terminal, transmission system, transmission method, and recording medium storing transmission control program
  Randomly Featured Patents
Bleed valve for axial flow compressor
Method and apparatus for data configuration in communication device
Ice detector for protecting boats
Endoscope having provision for repositioning a video sensor to a location which does not provide the same cross-sectionally viewed relationship with the distal end
Programmable apparatus and method for delivering microingredient feed additives by weight
Method and apparatus for remote installation of an operating system over a network connection
Method for determining a difference between a sub-Q code and a header of a CD-ROM
Segmentation of lesions in ultrasound images
Platelet activating factor antagonists, named "the phomactins", their preparation and use
Small-plaque variant canine herpesvirus vaccine